Absolute vs Relative Measures of Harm
View Presentation Qi Jiang, Amgen Inc. *Steven Snapinn, Amgen Inc. Keywords: safety evaluation, time-to-event endpoints, benefit:risk Harms caused by pharmaceutical treatments can be measured on absolute scales (for example, risk difference) or on relative scales (for example, relative risk), but there is no clear guidance on the situations for which one type of scale should be preferred over the other. The situation is analogous for the measurement of benefits; with respect to benefits we have previously shown that, when the clinical variable of interest is a time-to-event, the hazard ratio is preferred over absolute scales. In this presentation we extend that work to the evaluation of harms, and will consider the pros and cons of absolute and relative scales for safety endpoints, and for benefit:risk evaluation.
|
Key Dates
-
April 30 - May 22, 2013
Invited Abstract Submission Open -
June 4, 2013
Online Registration Opens -
August 9 - August 23, 2013
Invited Abstract Editing -
August 23, 2013
Short Course materials due from Instructors -
August 26, 2013
Housing Deadline -
September 9, 2013
Cancellation Deadline and Registration Closes @ 11:59 pm EDT -
September 16 - September 18, 2013
Marriott Wardman Park, Washington, DC